{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:46:04Z","timestamp":1761896764832,"version":"3.37.3"},"reference-count":38,"publisher":"Public Library of Science (PLoS)","issue":"4","license":[{"start":{"date-parts":[[2018,4,4]],"date-time":"2018-04-04T00:00:00Z","timestamp":1522800000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"TOSOH Corporation"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0195632","type":"journal-article","created":{"date-parts":[[2018,4,4]],"date-time":"2018-04-04T13:52:06Z","timestamp":1522849926000},"page":"e0195632","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":13,"title":["Changes in serum levels of autotaxin with direct-acting antiviral therapy in patients with chronic hepatitis C"],"prefix":"10.1371","volume":"13","author":[{"given":"Tomoo","family":"Yamazaki","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6364-9654","authenticated-orcid":true,"given":"Satoru","family":"Joshita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7985-919X","authenticated-orcid":true,"given":"Takeji","family":"Umemura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoko","family":"Usami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayumi","family":"Sugiura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoyuki","family":"Fujimori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takefumi","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akihiro","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koji","family":"Igarashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masao","family":"Ota","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eiji","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2018,4,4]]},"reference":[{"issue":"4","key":"ref1","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1002\/hep.1840120409","article-title":"Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: analysis by detection of antibody to hepatitis C virus","volume":"12","author":"K Kiyosawa","year":"1990","journal-title":"Hepatology"},{"issue":"Suppl 19","key":"ref2","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1007\/s00535-008-2251-0","article-title":"Epidemiology of hepatocellular carcinoma in Japan","volume":"44","author":"T Umemura","year":"2009","journal-title":"J Gastroenterol"},{"issue":"2","key":"ref3","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1002\/hep.23691","article-title":"Effect of aging on risk for hepatocellular carcinoma in chronic hepatitis C virus infection","volume":"52","author":"Y Asahina","year":"2010","journal-title":"Hepatology"},{"issue":"6","key":"ref4","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1002\/hep.27113","article-title":"Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection","volume":"59","author":"H Kumada","year":"2014","journal-title":"Hepatology"},{"issue":"11","key":"ref5","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1111\/jvh.12312","article-title":"Sofosbuvir plus ribavirin in Japanese patients with chronic genotype 2 HCV infection: an open-label, phase 3 trial","volume":"21","author":"M Omata","year":"2014","journal-title":"J Viral Hepat"},{"issue":"6","key":"ref6","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/S1473-3099(15)70099-X","article-title":"Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial","volume":"15","author":"M Mizokami","year":"2015","journal-title":"Lancet Infect Dis"},{"issue":"8","key":"ref7","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1111\/hepr.12621","article-title":"Daclatasvir and asunaprevir treatment improves liver function parameters and reduces liver fibrosis markers in chronic hepatitis C patients","volume":"46","author":"E Miyaki","year":"2016","journal-title":"Hepatology Research"},{"issue":"12","key":"ref8","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1111\/jvh.12578","article-title":"Regression of fibrosis and portal hypertension in HCV-associated cirrhosis and sustained virologic response after interferon-free antiviral therapy","volume":"23","author":"V Knop","year":"2016","journal-title":"J Viral Hepat"},{"key":"ref9","article-title":"Direct-Acting Antiviral Therapy for Chronic HCV Infection Results in Liver Stiffness Regression Over 12 Months Post-treatment","author":"J Chan","year":"2017","journal-title":"Dig Dis Sci"},{"issue":"3","key":"ref10","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/liv.13256","article-title":"Direct antiviral agent treatment of chronic hepatitis C results in rapid regression of transient elastography and fibrosis markers fibrosis-4 score and aspartate aminotransferase-platelet ratio index","volume":"37","author":"JA Bachofner","year":"2017","journal-title":"Liver Int"},{"issue":"2","key":"ref11","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1002\/jmv.24950","article-title":"Serial changes in liver stiffness and controlled attenuation parameter following direct-acting antiviral therapy against hepatitis C virus genotype 1b","volume":"90","author":"N Ogasawara","year":"2018","journal-title":"J Med Virol"},{"issue":"12","key":"ref12","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1111\/jgh.13788","article-title":"Improvement of liver stiffness in patients with hepatitis C virus infection who received direct-acting antiviral therapy and achieved sustained virological response","volume":"32","author":"T Tada","year":"2017","journal-title":"Journal of Gastroenterology and Hepatology"},{"issue":"42","key":"ref13","doi-asserted-by":"crossref","first-page":"39436","DOI":"10.1074\/jbc.M205623200","article-title":"Identification of human plasma lysophospholipase D, a lysophosphatidic acid-producing enzyme, as autotaxin, a multifunctional phosphodiesterase","volume":"277","author":"A Tokumura","year":"2002","journal-title":"J Biol Chem"},{"issue":"2","key":"ref14","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1083\/jcb.200206094","article-title":"Lysophospholipids in the limelight: autotaxin takes center stage","volume":"158","author":"WH Moolenaar","year":"2002","journal-title":"J Cell Biol"},{"issue":"8","key":"ref15","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1002\/bies.20081","article-title":"The ins and outs of lysophosphatidic acid signaling","volume":"26","author":"WH Moolenaar","year":"2004","journal-title":"Bioessays"},{"issue":"2","key":"ref16","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.canlet.2009.04.029","article-title":"Rapid clearance of the circulating metastatic factor autotaxin by the scavenger receptors of liver sinusoidal endothelial cells","volume":"284","author":"S Jansen","year":"2009","journal-title":"Cancer Lett"},{"issue":"12","key":"ref17","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/j.lfs.2007.08.013","article-title":"Plasma lysophosphatidic acid level and serum autotaxin activity are increased in liver injury in rats in relation to its severity","volume":"81","author":"N Watanabe","year":"2007","journal-title":"Life Sci"},{"issue":"13\u201314","key":"ref18","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1016\/j.cca.2011.03.014","article-title":"Autotaxin as a novel serum marker of liver fibrosis","volume":"412","author":"H Nakagawa","year":"2011","journal-title":"Clin Chim Acta"},{"issue":"23\u201324","key":"ref19","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1016\/j.cca.2012.07.014","article-title":"Autotaxin in liver fibrosis","volume":"413","author":"H Ikeda","year":"2012","journal-title":"Clin Chim Acta"},{"issue":"6","key":"ref20","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1097\/01.mcg.0000225642.90898.0e","article-title":"Both plasma lysophosphatidic acid and serum autotaxin levels are increased in chronic hepatitis C","volume":"41","author":"N Watanabe","year":"2007","journal-title":"J Clin Gastroenterol"},{"issue":"7","key":"ref21","doi-asserted-by":"crossref","first-page":"e103532","DOI":"10.1371\/journal.pone.0103532","article-title":"Serum autotaxin is a parameter for the severity of liver cirrhosis and overall survival in patients with liver cirrhosis\u2014a prospective cohort study","volume":"9","author":"T Pleli","year":"2014","journal-title":"PLoS One"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"46705","DOI":"10.1038\/srep46705","article-title":"Association of Serum Autotaxin Levels with Liver Fibrosis in Patients with Chronic Hepatitis C","volume":"7","author":"T Yamazaki","year":"2017","journal-title":"Sci Rep"},{"key":"ref23","article-title":"Serum autotaxin is a useful liver fibrosis marker in patients with chronic hepatitis B virus infection","author":"S Joshita","year":"2017","journal-title":"Hepatol Res"},{"issue":"9","key":"ref24","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1093\/infdis\/jiw372","article-title":"During Hepatitis C Virus (HCV) Infection and HCV-HIV Coinfection, an Elevated Plasma Level of Autotaxin Is Associated With Lysophosphatidic Acid and Markers of Immune Activation That Normalize During Interferon-Free HCV Therapy","volume":"214","author":"L Kostadinova","year":"2016","journal-title":"J Infect Dis"},{"issue":"1","key":"ref25","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/hep.20917","article-title":"Quantitative analysis of anti-hepatitis C virus antibody-secreting B cells in patients with chronic hepatitis C","volume":"43","author":"T Umemura","year":"2006","journal-title":"Hepatology"},{"issue":"7","key":"ref26","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.3851\/IMP1869","article-title":"Serum interleukin (IL)-10 and IL-12 levels and IL28B gene polymorphisms: pretreatment prediction of treatment failure in chronic hepatitis C","volume":"16","author":"T Umemura","year":"2011","journal-title":"Antivir Ther"},{"issue":"1\u20132","key":"ref27","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.cca.2007.10.005","article-title":"Validation of an autotaxin enzyme immunoassay in human serum samples and its application to hypoalbuminemia differentiation","volume":"388","author":"K Nakamura","year":"2008","journal-title":"Clin Chim Acta"},{"issue":"6","key":"ref28","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1002\/hep.21178","article-title":"Development of a simple noninvasive index to predict significant fibrosis in patients with HIV\/HCV coinfection","volume":"43","author":"RK Sterling","year":"2006","journal-title":"Hepatology"},{"issue":"2","key":"ref29","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1053\/jhep.2003.50346","article-title":"A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C","volume":"38","author":"CT Wai","year":"2003","journal-title":"Hepatology"},{"issue":"4","key":"ref30","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1002\/hep.28973","article-title":"Hepatocyte autotaxin expression promotes liver fibrosis and cancer","volume":"65","author":"E Kaffe","year":"2017","journal-title":"Hepatology"},{"issue":"21\u201322","key":"ref31","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1016\/j.cca.2011.06.039","article-title":"Serum autotaxin measurements in pregnant women: application for the differentiation of normal pregnancy and pregnancy-induced hypertension","volume":"412","author":"A Masuda","year":"2011","journal-title":"Clin Chim Acta"},{"issue":"1","key":"ref32","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1111\/j.1365-2141.2008.07325.x","article-title":"Serum autotaxin measurement in haematological malignancies: a promising marker for follicular lymphoma","volume":"143","author":"A Masuda","year":"2008","journal-title":"Br J Haematol"},{"issue":"6","key":"ref33","article-title":"Metabolomics analysis identifies sex-associated metabotypes of oxidative stress and the autotaxin-lysoPA axis in COPD","volume":"49","author":"S Naz","year":"2017","journal-title":"The European respiratory journal"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"11248","DOI":"10.1038\/ncomms11248","article-title":"Steroid binding to Autotaxin links bile salts and lysophosphatidic acid signalling","volume":"7","author":"W-J Keune","year":"2016","journal-title":"Nature Communications"},{"issue":"6","key":"ref35","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/j.ccell.2016.11.004","article-title":"Molecular Liver Cancer Prevention in Cirrhosis by Organ Transcriptome Analysis and Lysophosphatidic Acid Pathway Inhibition","volume":"30","author":"S Nakagawa","year":"2016","journal-title":"Cancer cell"},{"issue":"5","key":"ref36","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/j.jhep.2017.01.009","article-title":"Autotaxin-lysophosphatidic acid receptor signalling regulates hepatitis C virus replication","volume":"66","author":"MJ Farquhar","year":"2017","journal-title":"J Hepatol"},{"issue":"6","key":"ref37","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1038\/ajg.2015.118","article-title":"Serum Wisteria floribunda Agglutinin-Positive Mac-2-Binding Protein Level Predicts Liver Fibrosis and Prognosis in Primary Biliary Cirrhosis","volume":"110","author":"T Umemura","year":"2015","journal-title":"Am J Gastroenterol"},{"key":"ref38","article-title":"Serum Wisteria floribunda agglutinin-positive human Mac-2 binding protein may predict liver fibrosis and progression to hepatocellular carcinoma in patients with chronic hepatitis B virus infection","author":"Y Ichikawa","year":"2016","journal-title":"Hepatol Res"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0195632","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,10,20]],"date-time":"2018-10-20T12:03:55Z","timestamp":1540037035000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0195632"}},"subtitle":[],"editor":[{"given":"Tatsuo","family":"Kanda","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2018,4,4]]},"references-count":38,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2018,4,4]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0195632","relation":{},"ISSN":["1932-6203"],"issn-type":[{"type":"electronic","value":"1932-6203"}],"subject":[],"published":{"date-parts":[[2018,4,4]]}}}